🔴 REGULATORY
Bracco, ACIST win FDA clearance for ACIST Pro diagnostic system
Bracco and ACIST Medical Systems received FDA clearance for the ACIST Pro Diagnostic System, expanding their intravascular imaging portfolio.
Bracco can now leverage its contrast media distribution to push ACIST Pro into cath labs dominated by Philips IVUS and Abbott's Ultreon. Clinical superiority remains unproven — watch for prospective comparative data before adoption claims firm up.
Google News: CE mark ultrasound Europe MDR · Mon, 18 Ma
Read more →
🔵 RESEARCH
Meta-analysis tests ultrasound accuracy for medial knee injuries
A systematic review in The Ultrasound Journal evaluated ultrasound diagnostic accuracy for MCL and medial meniscus injuries against MRI and arthroscopy.
Cost-effective ultrasound could broaden first-line knee assessment, but pooled accuracy estimates risk masking operator-dependent variability. Clinicians should examine heterogeneity and subgroup performance before substituting ultrasound for MRI outside expert MSK centers.
⚪ INDUSTRY
Commentary: radiology AI's next frontier is patient understanding
A HIT Consultant opinion piece argues radiology AI's next use case is improving patient comprehension of imaging results, not diagnostic accuracy.
Signals a vendor pivot as diagnostic-accuracy differentiation plateaus. Patient-facing tools can wedge into workflows without FDA clearance, pressuring Nuance and Rad AI — but health literacy outcome data is missing, and the play may be monetization more than clinical value.
🩺 EDITOR’S TAKE — FOR CLINICIANS
Watch the cath lab and knee clinic: a new intravascular imaging option arrives just as ultrasound builds an evidence base against MRI for medial knee injuries. Both expand procedural choice but demand scrutiny of operator-dependent performance data.
📊 EDITOR’S TAKE — FOR INVESTORS
Bracco's ACIST Pro clearance signals a serious challenge to Philips and Abbott's IVUS lock on cath labs, leveraging existing contrast distribution. Meanwhile, radiology AI's pivot to patient-facing tools opens a non-510(k) workflow layer attractive to capital-light entrants.
🏭 EDITOR’S TAKE — FOR INDUSTRY
Two competitive pressures converge: incumbent intravascular imaging vendors face a contrast-media-backed challenger, and diagnostic AI vendors face commoditization pressure pushing them toward patient engagement layers — likely via Epic MyChart and portal integrations rather than standalone products.